andexanet alfa
E241384
Andexanet alfa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
All labels observed (1)
| Label | Occurrences |
|---|---|
| andexanet alfa canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190687 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: andexanet alfa Context triple: [Xarelto, hasAntidote, andexanet alfa]
-
A.
Anif
Anif is a small Austrian municipality near Salzburg, known for its historic castle and as a residence of notable figures.
-
B.
Enyo
Enyo is a Greek goddess of war and destruction, often depicted as a close companion and counterpart to the war god Ares.
-
C.
Alpha
Alpha is the first letter of the Greek alphabet, often symbolizing beginnings, primacy, or the starting point in various contexts.
-
D.
Alpha
Alpha is Sony’s line of interchangeable-lens mirrorless and DSLR-style digital cameras aimed at photography enthusiasts and professionals.
-
E.
ANA
ANA is the standard three-letter abbreviation used for the Anaheim Ducks, a professional ice hockey team in the National Hockey League.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: andexanet alfa Target entity description: Andexanet alfa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
A.
Anif
Anif is a small Austrian municipality near Salzburg, known for its historic castle and as a residence of notable figures.
-
B.
Enyo
Enyo is a Greek goddess of war and destruction, often depicted as a close companion and counterpart to the war god Ares.
-
C.
Alpha
Alpha is the first letter of the Greek alphabet, often symbolizing beginnings, primacy, or the starting point in various contexts.
-
D.
Alpha
Alpha is Sony’s line of interchangeable-lens mirrorless and DSLR-style digital cameras aimed at photography enthusiasts and professionals.
-
E.
ANA
ANA is the standard three-letter abbreviation used for the Anaheim Ducks, a professional ice hockey team in the National Hockey League.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
antidote
ⓘ
biologic drug ⓘ coagulation factor Xa decoy protein ⓘ reversal agent for factor Xa inhibitors ⓘ |
| approvalYear | 2018 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToClass |
anticoagulant reversal agents
ⓘ
hemostatic agents ⓘ |
| countryApprovedIn |
European Union
ⓘ
United States of America ⓘ
surface form:
United States
|
| derivedFrom | human factor Xa ⓘ |
| developedBy |
Alexion Pharmaceuticals
ⓘ
Portola Pharmaceuticals ⓘ |
| hasAdverseEffect |
cardiac arrest
ⓘ
infusion-related reactions ⓘ ischemic stroke ⓘ myocardial infarction ⓘ pneumonia ⓘ thromboembolic events ⓘ urinary tract infection ⓘ |
| hasATCCode | V03AB38 ⓘ |
| hasBlackBoxWarning | thromboembolic risk ⓘ |
| hasContraindication | known hypersensitivity to andexanet alfa ⓘ |
| hasDosageForm | intravenous solution ⓘ |
| hasGenericName | andexanet alfa self-link ⓘ |
| hasIndication |
reversal of anticoagulation due to apixaban
ⓘ
reversal of anticoagulation due to rivaroxaban ⓘ treatment of life-threatening bleeding in patients on factor Xa inhibitors ⓘ treatment of uncontrolled bleeding in patients on factor Xa inhibitors ⓘ |
| hasMolecularTarget |
apixaban
ⓘ
Xarelto ⓘ
surface form:
betrixaban
coagulation factor Xa ⓘ edoxaban ⓘ enoxaparin ⓘ Xarelto ⓘ
surface form:
rivaroxaban
|
| hasTradeName |
Andexxa
ⓘ
Ondexxya ⓘ |
| hasUNII | 9Z8WZ3Z3PO ⓘ |
| isExpensive | true ⓘ |
| isModifiedProtein | true ⓘ |
| isRecombinant | true ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mechanismOfAction |
acts as a decoy factor Xa that binds factor Xa inhibitors
ⓘ
restores thrombin generation ⓘ reverses anticoagulant effects of factor Xa inhibitors ⓘ |
| pharmacokineticProperty |
rapid onset of action
ⓘ
short half-life ⓘ |
| routeOfAdministration | intravenous ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: andexanet alfa Description of subject: Andexanet alfa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.